Proactive Investors
08 Dec 2025, 12:33 UTC · 41w ago
Verdict
Headline takes no side. We score AZN +1.00 across five claims — strongly bullish.
+1.00strongly bullish
More positive than 98% of ticker scores this week
What the story claims
5 claims · scored −1 bearish … +1 bullish
JPMorgan has named AstraZeneca its top UK healthcare pick for 2026, citing a catalyst-rich pipeline and high likelihood of clinical success.
More positive than 92% of claims this week
JPMorgan maintains an 'underweight' rating on GSK, warning of muted growth through 2030 and overly optimistic consensus forecasts.
So whatNegative outlooks on growth and forecasts from a major institution can trigger sell-offs or prevent a stock re-rating.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More negative than 91% of claims this week
JPMorgan upgraded Novartis to 'Overweight' based on the strength of its clinical pipeline.
More positive than 77% of claims this week
Bayer is identified as a potential 'dark horse' for 2026, contingent on gaining clarity regarding its litigation liabilities.
More positive than 63% of claims this week
Sanofi has been lowered to 'neutral' as analysts doubt its 2026 pipeline is strong enough to change market sentiment.
So whatA downgrade to neutral reflects a lack of conviction in growth catalysts, which often leads to stagnation or a slight decline in share price.
More negative than 71% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
JPMorgan placed the company at the top of its UK healthcare picks for 2026 due to a catalyst-rich pipeline.
More positive than 86% of ticker scores this week
Management described 2025 as a transformational year with strong performance results.
More negative than 85% of ticker scores this week
JPMorgan analysts remain 'underweight' with a muted growth outlook through 2030.
More positive than 86% of ticker scores this week
Highlighted as a potential top performer with a rich pipeline and an upgrade to Overweight.
More positive than 67% of ticker scores this week
Described as a 'dark horse' with improving business trends and potential for a re-rating if litigation liabilities are resolved.
More positive than 58% of ticker scores this week
Nudged up to Neutral following better-than-expected data for a breast cancer candidate.
More negative than 67% of ticker scores this week
Lowered to 'neutral' as analysts are unconvinced the 2026 pipeline offers enough firepower.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
8h ago
More positive than 56% of relationship scores this week
[mutual] Both are pharmaceutical companies noted for having catalyst-rich pipelines in global pharma.
More positive than 56% of relationship scores this week
[mutual] Both are pharmaceutical companies compared within JPMorgan's healthcare sector analysis.
−9.0%
Price is moving against the score
$163.33 vs $179.49 close before publication (Dec 5) · not market-adjusted
AZN chart →
